ReviewLiver cancer2014
Hepatic iron overload and hepatocellular carcinoma.
Review in Liver cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 3 syntheses or guidelines pooled it, 244 citations in OpenAlex.
- Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma.Cancer medicine · 2025Pooled it
- Pooled it
- The risk of new-onset cancer associated with HFE C282Y and H63D mutations: evidence from 87,028 participants.Journal of cellular and molecular medicine · 2016Pooled it
- Comparison of liver iron concentration calculated from R2* at 1.5 T and 3 T.Abdominal radiology (New York) · 2023Trial
- Iron Homeostasis and Liver Diseases.Journal of cellular and molecular medicine · 2026Review
- Bone marrow R2* correlates with liver iron load and is associated with decreased survival in patients with cirrhosis without liver iron overload.European radiology · 2026Article
- Quantitative assessment of pancreas R2* in cirrhosis with systemic iron overload: relationship with serum iron parameters and metabolic complications.Quantitative imaging in medicine and surgery · 2026Article
- Iron Overload: Pathophysiology, Diagnosis and Monitoring.International journal of laboratory hematology · 2026Review
- The role of iron in driving sex-biased differences in cancer.Cancer metastasis reviews · 2026Review
- Ferroptosis as a novel targeted therapy in gynecological malignant tumors.Discover oncology · 2026Review
- Assessing causal relationships between iron level, disorders of iron metabolism, and hepatocellular carcinoma: a Mendelian randomisation study : The first author.Discover oncology · 2026Article
- Arthritis and High Alcohol Intake at Diagnosis Increase Future Risk of Hepatocellular Carcinoma inGastro hep advances · 2026Article
- Review
- Exploring the Updated Roles of Ferroptosis in Liver Diseases: Mechanisms, Regulators, and Therapeutic Implications.Cell biochemistry and biophysics · 2025Review
- Article
- Assessing the effect of modifiable risk factors on hepatocellular carcinoma: evidence from a bidirectional Mendelian randomization analysis.Discover oncology · 2025Article
- MiR-10a-5p suppresses hepatocellular carcinoma progression and microvascular invasion by targeting TFR1-STAT3-CD24 signaling axis.Frontiers in oncology · 2025Article
- Geographic diversity of human liver cancers mirrors global social inequalities.Frontiers in oncology · 2025Review
- Review
- Prognostic iron-metabolism signature robustly stratifies single-cell characteristics of hepatocellular carcinoma.Computational and structural biotechnology journal · 2024Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years it has become increasingly evident that excess body iron may be complicated by the supervention of hepatocellular carcinoma (HCC). Hereditary hemochromatosis (HH) was the first condition in which hepatic iron overload was shown to predispose to the development of HCC. The inherited predisposition to excessive absorption of dietary iron in HH is almost always the result of homozygosity of the C282Y mutation of the HFE gene, which causes inappropriately low secretion of hepcidin. HCC develops in 8-10% of patients with HH and is responsible for approximately 45% of deaths in the HCC patients. Cirrhosis is almost always present when HCC is diagnosed. Dietary iron overload is a condition which occurs in rural-dwelling Black Africans in southern Africa as a result of the consumption, over time, of large volumes of alcohol home-brewed in iron containers and having, as a consequence, a high iron content. Iron loading of the liver results and may be complicated by malignant transformation of the liver (relative risk of approximately 10.0). Accompanying cirrhosis does occur but is less common than that in HH. The development of HCC as a consequence of increased dietary iron, and the fact that it may develop in the absence of cirrhosis, has been confirmed in an animal model. Drinking water with a high iron content might contribute to the high incidence of HCC in parts of Taiwan. The metabolic syndrome [obesity, insulin resistance type 2 (or diabetes mellitus type 2), non-alcoholic fatty liver or non-alcoholic steatohepatitis] has in recent years become a major public health problem in some resource-rich countries. A link between excess body iron and insulin resistance or the metabolic syndrome has become apparent. The metabolic syndrome may be complicated by the supervention of HCC, and recent evidence suggests that increased body iron may contribute to this complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.